Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
In a prospective analysis of 29,105 women from the Nurses’ Health Study II, greater consumption of ultraprocessed foods was associated with a 45% higher odds of early‑onset conventional colorectal adenomas, independent of obesity and
The randomized phase 2/3 DYNAMIC-III trial shows that postoperative circulating tumor DNA (ctDNA) strongly stratifies recurrence risk in stage III colon cancer. ctDNA-guided de-escalation reduced oxaliplatin exposure and hospitalizations wi
A pooled analysis of three US cohorts shows that maintaining guideline-level activity (~17 MET‑hours/week) consistently over decades is associated with substantial reductions in digestive system cancer incidence and mortality—comparable to
Two randomized trials found monthly olezarsen (50 mg and 80 mg) produced large, dose-dependent triglyceride reductions and a marked decrease in acute pancreatitis compared with placebo in patients with severe hypertriglyceridemia; higher do
A 2023 population survey of 4,002 adults in the UK and US found that positive screens for avoidant/restrictive food intake disorder (ARFID) were common among people with disorders of gut–brain interaction (DGBI) and associated with greater
An international survey of 533 clinicians shows hemodynamic status is the dominant factor shaping decisions about the timing of endoscopy for upper gastrointestinal bleeding; recommendations and practical pathways are summarized for clinici
A multicenter randomized trial shows electroacupuncture (EA) reduces time to first flatus and defecation and lowers prolonged POI after laparoscopic gastrectomy. Mechanistic plausibility, ERAS integration, and implementation challenges are
The LOVE‑CD phase 4 cohort shows vedolizumab yields higher sustained clinical and endoscopic remission and fewer serious adverse events when given early in Crohn’s disease versus later-stage, previously biologic‑exposed disease.
A phase 3 randomized trial in East Asia found oral etrasimod 2 mg superior to placebo for induction and maintenance of clinical remission in moderate–severe ulcerative colitis, with manageable safety and notable ALT elevations.
A clear, practical summary of the 2025 ERN position paper on fatigue in primary biliary cholangitis (PBC) — epidemiology, assessment, the ASK‑MEASURE‑TREAT algorithm, and research priorities.
A concise synthesis of a 2025 multistakeholder Lancet workshop consensus on population and clinical strategies to prevent, detect, and manage alcohol‑associated liver disease.
A large prospective cohort shows phosphatidylethanol (PEth) correlates with self-reported alcohol intake but identifies frequent under-reporting; adding PEth to diagnostic pathways could improve subclassification of steatotic liver disease
A global systematic review (110 cohorts, 50 countries) found substantial attrition across the hepatitis B care cascade: low rates of treatment eligibility assessment and antiviral initiation in primary/community models, poor retention parti
A multicentre observational study reports a 6% absolute fall in adenoma detection rate for non‑AI colonoscopies after clinicians were exposed to AI-assisted polyp detection—raising concerns about endoscopist deskilling and the need for safe
An epigenome-wide study (EPIC‑CD) identified peripheral blood DNA methylation panels that predicted response to vedolizumab and ustekinumab (validated AUC 0.75 each) but failed to predict adalimumab response. Models worked best in biologic‑
A blinded central-reader analysis of PREVENT ileocolonoscopy videos shows Rutgeerts, modified Rutgeerts, ileal REMIND, SES-CD and CDEIS are reliable and responsive in the neoterminal ileum, while performance is poorer at the anastomosis and
A new continuous index—EASE‑CD—focuses on ulcer presence, size, depth and proportion of ulcerated surface; it is reliable, responsive, and externally validated across two RCT datasets, offering a practical endoscopic endpoint for trials and
The phase 3 PRIMIS trial found cilofexor 100 mg once daily did not reduce histological fibrosis progression at 96 weeks in non‑cirrhotic primary sclerosing cholangitis; pruritus was more frequent with cilofexor.
This review synthesizes evidence from the phase 3 GLISTEN trial and preceding studies on linerixibat, an ileal bile acid transporter inhibitor, demonstrating its efficacy and safety in reducing cholestatic pruritus in primary biliary cholan
A UK–Ireland partnership ranked the top research uncertainties for oesophagogastric cancers; priorities emphasize personalising multimodal treatment, nutrition and quality of life, and stronger patient-centred trial design to accelerate mea
Open language-specific specialty feeds and department pages.